Company: SCYX
Filing Date: 2025-03-12
Form Type: 10-K
Source: 0000950170-25-038044
Chunk: 94

Company: SCYNEXIS INC
Filing Date: 2025-03-12
Form: 10-K
Item: Item 1A
Chunk 94
---
 described in this “Risk Factors” section and elsewhere in this report, may have a significant impact on the market price of our common stock:

•the level of sales of BREXAFEMME;

•the results of our preclinical testing or clinical trials;

•the ability to obtain additional funding;

•any delay in submitting an NDA or similar foreign applications for ibrexafungerp for the treatment of indications other than VVC, RVVC, and any future product candidate we may seek to develop or any adverse development or perceived adverse development with respect to the FDA’s review of that NDA or a foreign regulator’s review of a similar applications;

•maintenance of our existing collaborations or ability to enter into new collaborations;

•our collaboration partners’ election to develop or commercialize product candidates under our collaboration agreements or the termination of any programs under our collaboration agreements;

•any intellectual property infringement actions in which we or our licensors and collaboration partners may become involved;

•our ability to successfully develop and commercialize future product candidates;

•changes in laws or regulations applicable to future products;

•adverse regulatory decisions;

•introduction of new products, services or technologies by our competitors;

•achievement of financial projections we may provide to the public;

•achievement of the estimates and projections of the investment community;

•the perception of the pharmaceutical industry by the public, legislatures, regulators and the investment community;

•changes in the structure of healthcare payment systems;

•announcements of significant acquisitions, strategic partnerships, joint ventures or capital commitments by us, our collaboration partners or our competitors;

•disputes or other developments relating to proprietary rights, including patents, litigation matters and our ability to obtain patent protection for our technologies;

•legislation or regulation that mandates or encourages the use of generic products;

•additions or departures of key scientific or management personnel;

•significant lawsuits, including patent or stockholder litigation;

•changes in the market valuations of similar companies;

42

•general economic and market conditions and overall fluctuations in the U.S. equity markets;

•sales of our common stock by us, our executive officers and directors or our stockholders in the future; and

•trading volume of our common stock.

In addition, companies trading in the stock market in general, and the Nasdaq Global Market in particular, have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of these companies. Broad market and industry factors may negatively affect the market price of our common stock, regardless of our actual operating performance.

Future